GlassScriptPhysician profile
Sarah Campbell
NPI 1750910501
$3,936.90
in general payments reported to CMS, 2019-2025
17 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6.27 · 2023: $1,688 · 2024: $998 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,976 · Grant: $800 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,975.73 |
| Grant | $800.00 |
| Education | $154.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,377.27 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $561.32 | 2023-2025 | Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $507.09 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $490.03 | 2023-2025 | Cuvitru, Takhzyro |
| Grifols Shared Services North America, INC. | $186.75 | 2024 | Xembify |
| Tg Therapeutics, INC. | $161.01 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $154.90 | 2023-2024 | |
| Glaxosmithkline, LLC. | $98.28 | 2025 | Nucala, Trelegy Ellipta, Shingrix |
| Csl Behring | $81.54 | 2023-2025 | Hizentra |
| Biocryst US Sales Co., LLC | $79.78 | 2024-2025 | Orladeyo |
| Grifols USA, LLC | $63.36 | 2023-2024 | Xembify |
| Ionis Pharmaceuticals, INC. | $60.29 | 2025 | Dawnzera |
| Organon LLC | $32.76 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $32.44 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.43 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.02 | 2025 | Tezspire |
| Reprise Biomedical, INC. | $11.63 | 2025 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.